The Johnson & Johnson-funded Janssen vaccine demonstrates greater efficacy in a single dose, according to published results of the company’s safety and immunogenicity profile.
The effectiveness of single-dose results exceeds those requiring two. In addition, they point out that the antigen can be stored for three months at temperatures of minus 2 to 8 degrees Celsius.
With this publication, the company is ready to request emergency use in Mexico, where it is currently conducting clinical trials, as well as in other countries. However, they should be reviewed by bodies such as the Federal Health Protection Commission (Cofepris) or the Food and Drug Administration (FDA) of the United States.
According to the New England Journal of Medicine, neutralizing antibodies detected against wild-type viruses from 90 percent of participants on day 29 after the first dose of vaccine.
Neutralizing antibodies are proteins that are activated to protect the body from invasive viruses, which have reached one hundred percent protection on day 57, regardless of vaccine dose or age group. In addition, protection remained stable until at least day 71.
On day 14, CD4 T cell responses were detected in up to 83% of participants, ie white blood cells that fight infections and play an important role in the immune system.
CD8 + T cell responses were generally robust. These are cell-activated lymphocytes that have been infected with viruses and protected by antigen.
Despite the wide margin of response, the most common adverse or secondary events were fatigue, headache, myalgia, and discomfort at the injection site; the most common being fever. However, these effects were less common in those receiving the low dose vaccine, than in those who received two doses.
In terms of reactogenicity (frequent and “expected” side effects of the vaccine, especially excessive immune responses), it was lower after the second dose.
Multicenter, placebo-controlled studies, Sand were performed randomly on healthy adults between the ages of 18 and 55; as well as those over 65 years of age or older to receive the so-called Ad26.COV2 vaccine.
Johnson & Johnson reagent it can survive minus 20 degrees Celsius and can last three months, as long as it is maintained at temperatures between two and eight degrees; In addition, it does not require dilution to apply.
(…)
LP